本文關(guān)鍵詞： 結(jié)邊緣區(qū)淋巴瘤 利妥昔單抗 臨床分析　出處：《中國醫(yī)學(xué)科學(xué)院學(xué)報》2017年02期 　論文類型：期刊論文

【摘要】：目的總結(jié)淋巴結(jié)邊緣區(qū)淋巴瘤(NMZL)的臨床特點。方法回顧性分析本院2002年1月至2013年9月淋巴瘤中心住院診治的NMZL患者,總結(jié)臨床和實驗室檢查特點,并對治療療效、預(yù)后進(jìn)行統(tǒng)計分析。結(jié)果 24例經(jīng)病理證實的NMZL患者,中位年齡54.4(28~70)歲,男女比例1∶1。95%患者存在骨髓受累,乳酸脫氫酶增高40.9%(9/22),丙肝抗體陽性8.3%(2/24),自身抗體陽性33.3%(6/18),單克隆球蛋白陽性率33.3%(8/24)。所有患者CD19、CD20陽性,CD10陰性;CD5陽性率10%(1/10),CD23陽性率50%(5/10),但無CD5/CD23同時陽性患者。治療總緩解率81.25%,完全緩解率56.2%;應(yīng)用利妥昔單抗聯(lián)合化療較單純化療總緩解率及完全緩解率有提高趨勢,但差異無統(tǒng)計學(xué)意義(P=0.136,P=0.262)。結(jié)論結(jié)邊緣區(qū)淋巴瘤發(fā)病率低,男女發(fā)病率相當(dāng),容易骨髓侵犯;利妥昔單抗較單純化療組有可能提高療效(總緩解率及完全緩解率),甚至有可能改善無進(jìn)展生存。
[Abstract]:Objective to summarize the clinical features of lymph node marginal zone lymphoma (NMZL). Methods the clinical and laboratory features of NMZL patients hospitalized in our hospital from January 2002 to September 2013 were analyzed retrospectively. Results the median age of 24 patients with pathologically proved NMZL was 54.4- 2870 years old. The ratio of male and female was 1: 1.95% with bone marrow involvement. Lactate dehydrogenase was increased by 40.9% of 22%, hepatitis C antibody by 8.32%, autoantibody by 33.3% or 6 / 18, monoclonal globulin by 33.3% and by 8 / 24%. The positive rate of CD19 + CD20 + CD10 + CD10 negative CD10 + CD5 was 50% / 10% in all patients, but there was no CD5/CD23 positive at the same time. The total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%, and the total remission rate was 81.25%. The overall remission rate and complete remission rate of Rituximab combined chemotherapy were higher than those of chemotherapy alone. But the difference was not statistically significant. Conclusion the incidence of lymphomas in the marginal zone is low, the incidence of male and female is similar, and the incidence of bone marrow invasion is easy. Rituximab may improve the curative effect (total remission rate, complete remission rate, or even progressive survival rate) compared with chemotherapy alone group.
【作者單位】： 中國醫(yī)學(xué)科學(xué)院北京協(xié)和醫(yī)學(xué)院血液病醫(yī)院血液學(xué)研究所淋巴瘤中心;
【分類號】：R733.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉思管;樊娟;王欣;;利妥昔單抗治療難治性非霍奇金淋巴瘤9例療效觀察[J];山東醫(yī)藥;2007年23期

2 ;利妥昔單抗在慢性淋巴細(xì)胞白血病第2次Ⅲ期臨床試驗中獲得成功[J];國際藥學(xué)研究雜志;2009年02期

3 劉紅;張關(guān)敏;張艷華;;29例利妥昔單抗注射液不良反應(yīng)的臨床觀察與分析[J];中國醫(yī)院藥學(xué)雜志;2011年05期

4 劉一;胡小龍;王東;張波;;利妥昔單抗致肺損傷五例及文獻(xiàn)復(fù)習(xí)[J];中國呼吸與危重監(jiān)護(hù)雜志;2012年03期

5 蔡銘慈;趙維蒞;;利妥昔單抗在血液疾病中的臨床應(yīng)用[J];內(nèi)科理論與實踐;2012年02期

6 許昕;李慶山;朱志剛;朱國棟;朱園;;利妥昔單抗治療70歲以上老年非霍奇金淋巴瘤的療效與安全性[J];廣東醫(yī)學(xué);2012年12期

7 金t，

本文編號：1539077